Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial

Mostrar otras versiones (1)

Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) has anti-cancer effects and adverse events across a...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Yasuyoshi, Araki, Kyohei, Ohba, Kojiro, Mastuo, Tomhiro, Nakamura, Yuichiro, Yuno, Tsutomu, Mukai, Yuta, Otsubo, Asato, Mitsunari, Kensuke, Mochizuki, Yasushi, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403815/
https://www.ncbi.nlm.nih.gov/pubmed/32765876
http://dx.doi.org/10.3892/mco.2020.2099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403815/
https://www.ncbi.nlm.nih.gov/pubmed/32765876
http://dx.doi.org/10.3892/mco.2020.2099

Ejemplares similares